Trends in healthcare costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study.

Trends in healthcare costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study. J Gastroenterol Hepatol. 2017 Oct 21;: Authors: Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ Abstract BACKGROUND AND AIMS: Data regarding healthcare costs and utilization for IBD at the population level are limited in Asia. We aimed to investigate the nationwide prevalence, and healthcare cost and utilization of IBD in Korea. METHODS: We tracked the IBD-attributable healthcare costs and utilization from 2010 to 2014 using the…

Read More

Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease-Authors’ reply.

Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease-Authors’ reply. Aliment Pharmacol Ther. 2017 Nov;46(10):1026-1027 Authors: Feathers A, Swaminath A, Ananthakrishnan AN, Falzon L, Li Ferry S PMID: 29052855 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29052855?dopt=Abstract

Read More

Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Dig Dis Sci. 2017 Oct 20;: Authors: Campbell JP, Burton E, Wymer S, Shaw M, Vaughn BP Abstract BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed to optimize biologic therapy in inflammatory bowel disease (IBD). However, patients and physicians may be reluctant to perform TDM due to concerns related to potential out-of-pocket costs. AIMS: The aim of this study was to evaluate patient understanding and attitudes toward TDM in different clinical scenarios with and without potential out-of-pocket…

Read More

Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.

Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2017 Oct 20;: Authors: Calloway A, Dalal R, Beaulieu DB, Duley C, Annis K, Gaines L, Slaughter C, Schwartz DA, Horst S Abstract BACKGROUND: Noncompliance in use of anti-tumor necrosis factor (anti-TNF) therapy in patients with moderate-to-severe inflammatory bowel disease (IBD) can be a factor in medication failure. Few studies have evaluated the contribution of depressive symptoms to medication noncompliance in anti-TNF therapies. METHODS: A retrospective chart review was performed in a single-center…

Read More

Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn’s disease.

Related Articles Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Oct 20;: Authors: Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Begré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B, Swiss IBD Cohort Study Group Abstract BACKGROUND: Smoking is a strong environmental factor leading to adverse outcomes in Crohn’s disease, but a more benign course in ulcerative colitis. Several…

Read More

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

Related Articles Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Oct 13;: Authors: Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG Abstract BACKGROUND: Inflammatory bowel disease is a global disease in the 21st century. We aimed to assess the changing incidence and prevalence of inflammatory bowel disease around the world. METHODS: We searched MEDLINE and Embase up to and including Dec 31,…

Read More

The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.

Related Articles The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2017 Oct 20;: Authors: Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C Abstract BACKGROUND: Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota…

Read More
<< Go Back